Current status and future prospect of multimodality management of esophageal cancer.
- Author:
Jie HE
- Publication Type:Editorial
- MeSH:
Combined Modality Therapy;
Esophageal Neoplasms;
therapy;
Humans
- From:
Chinese Journal of Gastrointestinal Surgery
2011;14(9):657-659
- CountryChina
- Language:Chinese
-
Abstract:
The prevalence of esophageal cancer in China is significant. Surgery remains to be the mainstay treatment for esophageal cancer. Standardized surgical procedure and radical lymph node dissection is the base of multimodality treatment, which is also related to the success of the treatment and prognosis. At present, synchronized preoperative chemoradiation is recommended for operable esophageal cancer. Use of preoperative radiation is not associated with increased difficulty in performing surgery or increased complications. Preoperative chemotherapy alone is not recommended. NCCN recommends 5-fluorouracil-based adjuvant therapy administered synchronously with radiation. In China, postoperative synchronized chemoradiation is recommended for II(B-III) esophageal cancer. Large-scale, multi-center, prospective controlled clinical trials are warranted to determine the optimal combination of therapeutic alternatives to benefit patients the most.
